
Citius Pharmaceuticals Net Debt | CTXR
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Citius Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.44 M | -2.99 M | -26 M | -41 M | -69.2 M | -13.5 M | -7.72 M | -9.01 M | -3.03 M | 379 K | -676 K | -952 K | 3.21 K | 16.9 K | 18.3 K | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 379 K | -69.2 M | -11.8 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
TCR2 Therapeutics
TCRR
|
-7.6 M | - | - | $ 58.1 M | ||
|
ASLAN Pharmaceuticals Limited
ASLN
|
-13.8 M | - | -14.27 % | $ 1.7 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
BELLUS Health
BLU
|
-86 M | - | - | $ 2.47 B | ||
|
Intra-Cellular Therapies
ITCI
|
-290 M | - | - | $ 13.6 B | ||
|
Marinus Pharmaceuticals
MRNS
|
-44.8 M | - | - | $ 29.6 M | ||
|
GeoVax Labs
GOVX
|
-2.82 M | $ 1.83 | -4.45 % | $ 8.35 M | ||
|
Unity Biotechnology
UBX
|
16 M | - | -33.41 % | $ 3.37 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Tyme Technologies
TYME
|
-107 M | - | 8.07 % | $ 54 M | ||
|
Karuna Therapeutics
KRTX
|
-169 M | - | - | $ 12.2 B | ||
|
Revance Therapeutics
RVNC
|
295 M | - | - | $ 309 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
TRACON Pharmaceuticals
TCON
|
-28 M | - | -1.38 % | $ 46.8 M | ||
|
Forward Pharma A/S
FWP
|
-57.9 M | - | -0.75 % | $ 18.7 M | ||
|
9 Meters Biopharma
NMTR
|
-12.5 M | - | -42.97 % | $ 1.05 M | ||
|
Theratechnologies
THTX
|
-14.7 M | - | - | $ 83.9 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-36.2 M | - | -15.15 % | $ 60.3 M | ||
|
TFF Pharmaceuticals
TFFP
|
-5.36 M | - | -60.05 % | $ 125 K | ||
|
Codiak BioSciences
CDAK
|
-39.4 M | - | -55.98 % | $ 2.15 M | ||
|
Sage Therapeutics
SAGE
|
-69.2 M | - | - | $ 527 M | ||
|
Paratek Pharmaceuticals
PRTK
|
223 M | - | - | $ 121 M | ||
|
AVEO Pharmaceuticals
AVEO
|
-61.1 M | - | - | $ 521 M | ||
|
Cyclerion Therapeutics
CYCN
|
-12.2 M | $ 34.99 | 3.77 % | $ 147 M | ||
|
Seelos Therapeutics
SEEL
|
11.2 M | - | -47.76 % | $ 6.27 M | ||
|
Завод ДИОД
DIOD
|
-48.6 M | - | - | - | ||
|
Kiromic BioPharma
KRBP
|
-224 K | - | 6.61 % | $ 3.08 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
-57.6 M | - | - | $ 2.18 B | ||
|
Fusion Pharmaceuticals
FUSN
|
-22.5 M | - | - | $ 1.41 B | ||
|
Gritstone Oncology
GRTS
|
-15.9 M | - | 0.42 % | $ 213 M | ||
|
Aridis Pharmaceuticals
ARDS
|
-3.05 M | - | 17.91 % | $ 11.1 M | ||
|
Titan Pharmaceuticals
TTNP
|
-2.75 M | - | -3.76 % | $ 3.47 M | ||
|
HOOKIPA Pharma
HOOK
|
-38.8 M | - | -6.92 % | $ 79.4 M | ||
|
Otonomy
OTIC
|
-58.1 M | - | -1.96 % | $ 4.68 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
-174 M | $ 286.96 | 0.01 % | $ 5.55 B | ||
|
Фармсинтез
LIFE
|
612 M | - | - | - | ||
|
Actinium Pharmaceuticals
ATNM
|
-46.3 M | $ 1.04 | -4.59 % | $ 32.4 M | ||
|
Oncternal Therapeutics
ONCT
|
-6.38 M | - | -24.12 % | $ 1.56 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Concert Pharmaceuticals
CNCE
|
-127 M | - | - | $ 401 M | ||
|
Histogen
HSTO
|
-11.9 M | - | 31.6 % | $ 2.12 M | ||
|
Checkpoint Therapeutics
CKPT
|
-40.8 M | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
293 M | - | -7.23 % | $ 13 M | ||
|
Taro Pharmaceutical Industries Ltd.
TARO
|
-513 M | - | - | $ 1.62 B | ||
|
Omeros Corporation
OMER
|
84 M | $ 13.23 | -5.71 % | $ 840 M | ||
|
BioLineRx Ltd.
BLRX
|
-2.04 M | $ 0.94 | -10.44 % | $ 2.32 B | ||
|
PhaseBio Pharmaceuticals
PHAS
|
-39.4 M | - | 7.4 % | $ 6.29 M | ||
|
Forma Therapeutics Holdings
FMTX
|
-44.7 M | - | - | $ 958 M |